Vaprisol is a drug owned by Cumberland Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 15, 2019. Details of Vaprisol's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5723606 | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(4 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Vaprisol is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vaprisol's family patents as well as insights into ongoing legal events on those patents.
Vaprisol's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vaprisol's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 15, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vaprisol Generics:
There are no approved generic versions for Vaprisol as of now.
Alternative Brands for Vaprisol
Vaprisol which is used for intravenous treatment of patients with hypervolemic hyponatremia., has several other brand drugs in the same treatment category and using the same active ingredient (Conivaptan Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Cumberland |
| |||
About Vaprisol
Vaprisol is a drug owned by Cumberland Pharmaceuticals Inc. It is used for intravenous treatment of patients with hypervolemic hyponatremia. Vaprisol uses Conivaptan Hydrochloride as an active ingredient. Vaprisol was launched by Cumberland in 2005.
Approval Date:
Vaprisol was approved by FDA for market use on 29 December, 2005.
Active Ingredient:
Vaprisol uses Conivaptan Hydrochloride as the active ingredient. Check out other Drugs and Companies using Conivaptan Hydrochloride ingredient
Treatment:
Vaprisol is used for intravenous treatment of patients with hypervolemic hyponatremia.
Dosage:
Vaprisol is available in injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/4ML (5MG/ML) | INJECTABLE | Discontinued | INTRAVENOUS |